X-Received: by 2002:a05:6214:3001:b0:46e:762d:e53e with SMTP id ke1-20020a056214300100b0046e762de53emr24872112qvb.125.1656877491169;
Sun, 03 Jul 2022 12:44:51 -0700 (PDT)
X-Received: by 2002:a05:6870:3102:b0:101:15a2:9d7f with SMTP id
v2-20020a056870310200b0010115a29d7fmr14545876oaa.36.1656877490958; Sun, 03
Jul 2022 12:44:50 -0700 (PDT)
Path: i2pn2.org!i2pn.org!usenet.blueworldhosting.com!feed1.usenet.blueworldhosting.com!peer02.iad!feed-me.highwinds-media.com!news.highwinds-media.com!news-out.google.com!nntp.google.com!postnews.google.com!google-groups.googlegroups.com!not-for-mail
Newsgroups: comp.os.cpm
Date: Sun, 3 Jul 2022 12:44:50 -0700 (PDT)
Injection-Info: google-groups.googlegroups.com; posting-host=155.94.216.100; posting-account=uMUGLQoAAAAoOKgG8uaQ7UiwufdxK7QN
NNTP-Posting-Host: 155.94.216.100
User-Agent: G2/1.0
MIME-Version: 1.0
Message-ID: <08e5a344-7a92-42b9-91bf-48bb0f1ae659n@googlegroups.com>
Subject: (PDF) Fragment-based Drug Discovery - Lessons and Outlook by Erlanson
From: hesterholt14@gmail.com (hester holt)
Injection-Date: Sun, 03 Jul 2022 19:44:51 +0000
Content-Type: text/plain; charset="UTF-8"
X-Received-Bytes: 1249